France Archives

News and Trends 17 Mar 2016

“We have Reshaped how Innovation occurs inside Pierre Fabre”

This is what Laurent Audoly, Head of R&D of Pierre Fabre, told me at the SACHS conference in Zurich last Tuesday. The French Big Pharma recently opened its fund for innovation and it was a great opportunity to get a better insight into it. Pierre Fabre is the 3rd largest Pharma in France, counting over […]

March 17, 2016 - 1 minutemin - By Philip Hemme

gecko surgical adhesive sofinnova bpifrance

News and Trends 17 Mar 2016

Leading European VC believes this is the “Post-It of Surgery”

Gecko Biomedical (France) has raised €22.5M to get its innovate biopolymers to surgery rooms, and caught the eye of the biggest French Biotech investor, Sofinnova. Gecko has a hot piece of MedTech in its hands: a surgical glue that can stop bleeding from sutured tissues, and in the future could replace stitching altogether. This technology was […]

March 17, 2016 - 3 minutesmins - By Denise Neves Gameiro

cellectis ucart leukemia cancer gmp manufacturing ucart19 ucart123 allogeneic universal 2015 financial results

News and Trends 16 Mar 2016

How Good was 2015 for the French Universal CAR-T Biotech?

Cellectis (France) has now released its financial results for 2015. What happened and what the prospects for 2016 and long-term? It was a really packed year for Cellectis, the French Champion for universal, off-the-shelf CAR-T treatments. The Biopharma saw significant advances in multiple fronts, from clinical development to financing. The first therapy initially developed by […]

March 16, 2016 - 3 minutesmins - By Denise Neves Gameiro

deinove deinococci biorefinery green chemistry arbiom biomass wood pretreatment lignin optafuel biomethodes bioskog

News and Trends 15 Mar 2016

French SynBio Biotech to ferment wood for Carbon-free Future

Deinove (Montpelier) and Arbiom (Evry) are two Biotechs from France which have now partnered to transform wood residues into added-value chemicals – a step closer to the ideal Bioeconomy. Deinove is one of our favourite Green Chemistry and SynBio Biotechs, developing micro-factories with their library of Deinococcus. Its projects range from using tobacco plants to making carotenoids, also with […]

March 15, 2016 - 3 minutesmins - By Denise Neves Gameiro

nanobiotix private placement €21M nanoxray sarcoma liver head neck prostate cancer nbtxr3 nanomedicine radiotherapy localized

News and Trends 15 Mar 2016

French Nanomedicine Biotech Gets €21M to Kill Cancer with ‘Beam Rays’

Nanobiotix (France) has had a successful private placement in, raising €21.3M to advance the clinical development of its localised radiotherapy for Cancer. Located in Paris’ superbiocluster, Nanobiotix wants to change the way cancer is treated – but in a different way from most Biotech strategies. It is developing NanoXRay, a paradigm-shifting nanotechnology for localised radiotherapy. Nanobiotix has […]

March 15, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 14 Mar 2016

DBV: “These Additional Results Confirm our Potential of solving the Peanut Allergy problem Worldwide”

DBV Technologies (Paris) was just under the spotlight in Los Angeles at the biggest allergy convention worldwide (2016 AAAAI Annual Meeting). Their Viaskin skin patch could potentially eradicate peanut allergies for patients altogether… Last year, it was the first French Biotech to be listed on the NASDAQ (raising €90M), it then raised €255M (!) in a follow-up round […]

March 14, 2016 - 6 minutesmins - By Philip Hemme

genfit nash fatty liver disease elfibranor PPAR phase III resolve it

News and Trends 11 Mar 2016

Genfit Has Enroled its First Patient in a NASH Phase III Trial

Genfit (France) has enroled their first patient in the highly anticipated phase III trial (RESOLVE-IT) for NASH, a fatty-liver disease currently without any approved treatment. This is good news for Genfit, which managed to kickstart a phase III trial for their lead candidate, Elafibranor, just one year after the read-out of the phase IIb results. There […]

March 11, 2016 - 2 minutesmins - By Denise Neves Gameiro

edna environment conservation genetics biotech freshwater biodiversity spygen newts

News and Trends 10 Mar 2016

How this Forensic DNA Tool can help Conserve Endangered Species in the UK

This is the story of how the Natural History Museum of Denmark and Molecular Ecology biotech Spygen (France) brought together forensic science techniques to detect traces of Great Crested Newt DNA in UK ponds. The Great Crested Newt (Triturus cristatus) is an amphibian found across Northern Europe and parts of Asia, which has been declining since […]

March 10, 2016 - 3 minutesmins - By Joachim Eeckhout

genzyme sanofi enzyme replacement therapy pompe disease neogaa neo1

News and Trends 8 Mar 2016

Sanofi Genzyme goes to Phase III with Rare Neuromuscular Disease

Sanofi Genzyme (Boston and France) have obtained good phase I/II results with a candidate for the rare Pompe Disease and expects to move to phase III in the second quarter of 2016. Sanofi Genzyme continues to bet on rare diseases and neurodegenerative disorders, now with a therapy for late-onset Pompe Disease. Pompe Disease is a […]

March 8, 2016 - 2 minutesmins - By Denise Neves Gameiro

crispr mimivire aix nature virus synbio biotech

News and Trends 4 Mar 2016

This Megavirus has its own CRISPR-like Defense System

MIMIVIRE is the name French researchers have given to the immunity mechanism of mimivirus, and that they have now described in a new paper for Nature. What is a mimivirus? What is viral immunity? What is life? What is CRISPR? Well, for the last question, you should read our review on CRISPR. As for the rest, […]

March 4, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 1 Mar 2016

Artificial Hearts are one Step Closer to the Market with €50M in Funding

Carmat (France) has raised €50M from private investors (dwarfing its 2015’s €3M reserves) in order to further develop its artificial hearts during 2016 and apply for CE Marking. This French Medtech company is developing an artificial heart (one of top examples of futuristic cyborg-like technologies in biotech) that could help patients with end-stage biventricular heart failure. There are people […]

March 1, 2016 - 2 minutesmins - By Denise Neves Gameiro

exelixis ipsen cancercabozantinib renal liver endometrial nsclc

News and Trends 1 Mar 2016

French Ipsen closes €700M deal for Californian Cancer Drug

Ipsen is paying Exelixis $200M upfront, plus $545M in future milestones to acquire commercialization rights for a multi-organ cancer candidate outside US, Canada and Japan. California-based Exelixis has found an European partner to license the small molecule drug, cabozantinib. Ipsen, a French biotech group, will have comercialization rights for cabozantinib worldwide, except in the US and […]

March 1, 2016 - 2 minutesmins - By Denise Neves Gameiro

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

France

“We have Reshaped how Innovation occurs inside Pierre Fabre”

Leading European VC believes this is the “Post-It of Surgery”

How Good was 2015 for the French Universal CAR-T Biotech?

French SynBio Biotech to ferment wood for Carbon-free Future

French Nanomedicine Biotech Gets €21M to Kill Cancer with ‘Beam Rays’

DBV: “These Additional Results Confirm our Potential of solving the Peanut Allergy problem Worldwide”

Genfit Has Enroled its First Patient in a NASH Phase III Trial

How this Forensic DNA Tool can help Conserve Endangered Species in the UK

Sanofi Genzyme goes to Phase III with Rare Neuromuscular Disease

This Megavirus has its own CRISPR-like Defense System

Artificial Hearts are one Step Closer to the Market with €50M in Funding

French Ipsen closes €700M deal for Californian Cancer Drug

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!